StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen total assets

Total assets on the balance sheet at the end of each period.

Repligen's total assets was $2.93B at Sep 30, 2026. For fiscal 2025 it was $2.95B, up 4.2% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $2.95B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.95B+4.2%
FY2024Dec 31, 2024$2.83B-0.1%
FY2023Dec 31, 2023$2.83B+11.8%
FY2022Dec 31, 2022$2.53B+7.3%
FY2021Dec 31, 2021$2.36B+23.9%
FY2020Dec 31, 2020$1.90B+35.9%
FY2019Dec 31, 2019$1.40B+80.7%
FY2018Dec 31, 2018$774.62M+4.2%
FY2017Dec 31, 2017$743.52M+157.4%
FY2016Dec 31, 2016$288.91M+97.6%
FY2015Dec 31, 2015$146.24M+14.0%
FY2014Dec 31, 2014$128.29M+8.1%
FY2013Dec 31, 2013$118.64M+64.1%
FY2011Mar 31, 2011$72.29M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.93B+0.1%
Q2 FY2026Jun 30, 2026$2.95B+1.7%
Q1 FY2026Mar 31, 2026$2.93B+2.8%
Q4 FY2025Dec 31, 2025$2.95B+4.2%
Q3 FY2025Sep 30, 2025$2.92B+3.3%
Q2 FY2025Jun 30, 2025$2.90B+1.2%
Q1 FY2025Mar 31, 2025$2.85B-0.1%
Q4 FY2024Dec 31, 2024$2.83B-0.1%
Q3 FY2024Sep 30, 2024$2.83B+12.2%
Q2 FY2024Jun 30, 2024$2.87B+12.1%
Q1 FY2024Mar 31, 2024$2.85B+12.0%
Q4 FY2023Dec 31, 2023$2.83B+11.8%
Q3 FY2023Sep 30, 2023$2.52B+2.4%
Q2 FY2023Jun 30, 2023$2.56B+4.6%
Q1 FY2023Mar 31, 2023$2.55B+6.9%
Q4 FY2022Dec 31, 2022$2.53B+7.3%
Q3 FY2022Sep 30, 2022$2.46B+9.9%
Q2 FY2022Jun 30, 2022$2.44B+21.3%
Q1 FY2022Mar 31, 2022$2.38B+23.7%
Q4 FY2021Dec 31, 2021$2.36B+23.9%
Q3 FY2021Sep 30, 2021$2.24B+51.8%
Q2 FY2021Jun 30, 2021$2.02B+39.8%
Q1 FY2021Mar 31, 2021$1.93B+37.0%
Q4 FY2020Dec 31, 2020$1.90B+35.9%
Q3 FY2020Sep 30, 2020$1.48B+7.1%
Q2 FY2020Jun 30, 2020$1.44B+35.0%
Q1 FY2020Mar 31, 2020$1.41B+76.3%
Q4 FY2019Dec 31, 2019$1.40B+80.7%
Q3 FY2019Sep 30, 2019$1.38B+80.9%
Q2 FY2019Jun 30, 2019$1.07B+43.4%
Q1 FY2019Mar 31, 2019$797.92M+7.4%
Q4 FY2018Dec 31, 2018$774.62M+4.2%
Q3 FY2018Sep 30, 2018$762.13M+3.8%
Q2 FY2018Jun 30, 2018$745.08M+141.3%
Q1 FY2018Mar 31, 2018$743.25M+155.7%
Q4 FY2017Dec 31, 2017$743.52M+157.4%
Q3 FY2017Sep 30, 2017$734.24M–
Q2 FY2017Jun 30, 2017$308.76M–
Q1 FY2017Mar 31, 2017$290.63M–
Q4 FY2016Dec 31, 2016$288.91M–

More Repligen figures

See a number that looks wrong?